Report cover image

Global Depression-MDD Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 194 Pages
SKU # APRC20355982

Description

Summary

According to APO Research, The global Depression-MDD Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Depression-MDD Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Depression-MDD Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Depression-MDD Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Depression-MDD Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Depression-MDD Drugs include Merck, Eli Lilly, Pfizer, GlaxoSmithKline, AstraZeneca, Teva Pharmaceutical Industries, Reviva Pharmaceuticals Holdings, Janssen Pharmaceuticals and H. Lundbeck, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Depression-MDD Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Depression-MDD Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Depression-MDD Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Depression-MDD Drugs revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Depression-MDD Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Depression-MDD Drugs revenue, projected growth trends, production technology, application and end-user industry.

Depression-MDD Drugs Segment by Company

Merck
Eli Lilly
Pfizer
GlaxoSmithKline
AstraZeneca
Teva Pharmaceutical Industries
Reviva Pharmaceuticals Holdings
Janssen Pharmaceuticals
H. Lundbeck
Bristol-Myers Squibb
Depression-MDD Drugs Segment by Type

Selective Serotonin Reuptake Inhibitors,
Tricyclic Antidepressants
Atypical Antidepressants
Serotonin & Norepinephrine Reuptake Inhibitors
Depression-MDD Drugs Segment by Application

Online Pharmacy
Pharmacy
Hospital
Other
Depression-MDD Drugs Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Depression-MDD Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Depression-MDD Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Depression-MDD Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Depression-MDD Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Depression-MDD Drugs industry.
Chapter 3: Detailed analysis of Depression-MDD Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Depression-MDD Drugsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.

Table of Contents

194 Pages
1 Market Overview
1.1 Product Definition
1.2 Market Analysis by Type
1.2.1 Global Depression-MDD Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Selective Serotonin Reuptake Inhibitors,
1.2.3 Tricyclic Antidepressants
1.2.4 Atypical Antidepressants
1.2.5 Serotonin & Norepinephrine Reuptake Inhibitors
1.3 Market Analysis by Application
1.3.1 Global Depression-MDD Drugs Market Size Growth Rate by Application: 2020 VS 2024 VS 2031
1.3.2 Online Pharmacy
1.3.3 Pharmacy
1.3.4 Hospital
1.3.5 Other
1.4 Global Market Growth Prospects
1.5 Global Depression-MDD Drugs Growth Trends by Region
1.5.1 Global Depression-MDD Drugs Market Size by Region: 2020 VS 2024 VS 2031
1.5.2 Depression-MDD Drugs Market Size by Region (2020-2025)
1.5.3 Depression-MDD Drugs Market Size by Region (2026-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
1.8 Years Considered
2 Global Depression-MDD Drugs Market Dynamics
2.1 Depression-MDD Drugs Industry Trends
2.2 Depression-MDD Drugs Industry Drivers
2.3 Depression-MDD Drugs Industry Opportunities and Challenges
2.4 Depression-MDD Drugs Industry Restraints
3 Competitive Landscape by Company
3.1 Global Depression-MDD Drugs Revenue by Company (2020-2025)
3.2 Global Depression-MDD Drugs Players Revenue Ranking, 2023 VS 2024 VS 2025
3.3 Global Depression-MDD Drugs Key Company Head office and Area Served
3.4 Global Depression-MDD Drugs Company, Product Type & Application
3.5 Global Depression-MDD Drugs Company Establishment Date
3.6 Market Competitive Analysis
3.6.1 Global Depression-MDD Drugs Market CR5 and HHI
3.6.2 Global Top 5 and 10 Depression-MDD Drugs Players Market Share by Revenue in 2024
3.6.3 2024 Depression-MDD Drugs Tier 1, Tier 2, and Tier 3
4 Depression-MDD Drugs Market by Type
4.1 Global Depression-MDD Drugs Market Size by Type (2020 VS 2024 VS 2031)
4.2 Global Depression-MDD Drugs Market Size by Type (2020-2031)
4.3 Global Depression-MDD Drugs Market Size Share by Type (2020-2031)
5 Depression-MDD Drugs Market by Application
5.1 Global Depression-MDD Drugs Market Size by Application (2020 VS 2024 VS 2031)
5.2 Global Depression-MDD Drugs Market Size by Application (2020-2031)
5.3 Global Depression-MDD Drugs Market Size Share by Application (2020-2031)
6 Company Profiles
6.1 Merck
6.1.1 Merck Comapny Information
6.1.2 Merck Business Overview
6.1.3 Merck Depression-MDD Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.1.4 Merck Depression-MDD Drugs Product Portfolio
6.1.5 Merck Recent Developments
6.2 Eli Lilly
6.2.1 Eli Lilly Comapny Information
6.2.2 Eli Lilly Business Overview
6.2.3 Eli Lilly Depression-MDD Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.2.4 Eli Lilly Depression-MDD Drugs Product Portfolio
6.2.5 Eli Lilly Recent Developments
6.3 Pfizer
6.3.1 Pfizer Comapny Information
6.3.2 Pfizer Business Overview
6.3.3 Pfizer Depression-MDD Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.3.4 Pfizer Depression-MDD Drugs Product Portfolio
6.3.5 Pfizer Recent Developments
6.4 GlaxoSmithKline
6.4.1 GlaxoSmithKline Comapny Information
6.4.2 GlaxoSmithKline Business Overview
6.4.3 GlaxoSmithKline Depression-MDD Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.4.4 GlaxoSmithKline Depression-MDD Drugs Product Portfolio
6.4.5 GlaxoSmithKline Recent Developments
6.5 AstraZeneca
6.5.1 AstraZeneca Comapny Information
6.5.2 AstraZeneca Business Overview
6.5.3 AstraZeneca Depression-MDD Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.5.4 AstraZeneca Depression-MDD Drugs Product Portfolio
6.5.5 AstraZeneca Recent Developments
6.6 Teva Pharmaceutical Industries
6.6.1 Teva Pharmaceutical Industries Comapny Information
6.6.2 Teva Pharmaceutical Industries Business Overview
6.6.3 Teva Pharmaceutical Industries Depression-MDD Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.6.4 Teva Pharmaceutical Industries Depression-MDD Drugs Product Portfolio
6.6.5 Teva Pharmaceutical Industries Recent Developments
6.7 Reviva Pharmaceuticals Holdings
6.7.1 Reviva Pharmaceuticals Holdings Comapny Information
6.7.2 Reviva Pharmaceuticals Holdings Business Overview
6.7.3 Reviva Pharmaceuticals Holdings Depression-MDD Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.7.4 Reviva Pharmaceuticals Holdings Depression-MDD Drugs Product Portfolio
6.7.5 Reviva Pharmaceuticals Holdings Recent Developments
6.8 Janssen Pharmaceuticals
6.8.1 Janssen Pharmaceuticals Comapny Information
6.8.2 Janssen Pharmaceuticals Business Overview
6.8.3 Janssen Pharmaceuticals Depression-MDD Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.8.4 Janssen Pharmaceuticals Depression-MDD Drugs Product Portfolio
6.8.5 Janssen Pharmaceuticals Recent Developments
6.9 H. Lundbeck
6.9.1 H. Lundbeck Comapny Information
6.9.2 H. Lundbeck Business Overview
6.9.3 H. Lundbeck Depression-MDD Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.9.4 H. Lundbeck Depression-MDD Drugs Product Portfolio
6.9.5 H. Lundbeck Recent Developments
6.10 Bristol-Myers Squibb
6.10.1 Bristol-Myers Squibb Comapny Information
6.10.2 Bristol-Myers Squibb Business Overview
6.10.3 Bristol-Myers Squibb Depression-MDD Drugs Revenue and Gross Margin (US$ Million) & (2020-2025)
6.10.4 Bristol-Myers Squibb Depression-MDD Drugs Product Portfolio
6.10.5 Bristol-Myers Squibb Recent Developments
7 North America
7.1 North America Depression-MDD Drugs Market Size (2020-2031)
7.2 North America Depression-MDD Drugs Market Size by Type
7.2.1 North America Depression-MDD Drugs Market Size by Type (2020-2025)
7.2.2 North America Depression-MDD Drugs Market Size by Type (2026-2031)
7.2.3 North America Depression-MDD Drugs Market Share by Type (2020-2031)
7.3 North America Depression-MDD Drugs Market Size by Application
7.3.1 North America Depression-MDD Drugs Market Size by Application (2020-2025)
7.3.2 North America Depression-MDD Drugs Market Size by Application (2026-2031)
7.3.3 North America Depression-MDD Drugs Market Share by Application (2020-2031)
7.4 North America Depression-MDD Drugs Market Size by Country
7.4.1 North America Depression-MDD Drugs Market Size by Country (2020 VS 2024 VS 2031)
7.4.2 North America Depression-MDD Drugs Market Size by Country (2020-2025)
7.4.3 North America Depression-MDD Drugs Market Size by Country (2026-2031)
7.4.4 North America Depression-MDD Drugs Market Share by Country (2020-2031)
7.4.5 United States
7.4.6 Canada
7.4.7 Mexico
8 Europe
8.1 Europe Depression-MDD Drugs Market Size (2020-2031)
8.2 Europe Depression-MDD Drugs Market Size by Type
8.2.1 Europe Depression-MDD Drugs Market Size by Type (2020-2025)
8.2.2 Europe Depression-MDD Drugs Market Size by Type (2026-2031)
8.2.3 Europe Depression-MDD Drugs Market Share by Type (2020-2031)
8.3 Europe Depression-MDD Drugs Market Size by Application
8.3.1 Europe Depression-MDD Drugs Market Size by Application (2020-2025)
8.3.2 Europe Depression-MDD Drugs Market Size by Application (2026-2031)
8.3.3 Europe Depression-MDD Drugs Market Share by Application (2020-2031)
8.4 Europe Depression-MDD Drugs Market Size by Country
8.4.1 Europe Depression-MDD Drugs Market Size by Country (2020 VS 2024 VS 2031)
8.4.2 Europe Depression-MDD Drugs Market Size by Country (2020-2025)
8.4.3 Europe Depression-MDD Drugs Market Size by Country (2026-2031)
8.4.4 Europe Depression-MDD Drugs Market Share by Country (2020-2031)
8.4.5 Germany
8.4.6 France
8.4.7 U.K.
8.4.8 Italy
8.4.9 Russia
8.4.10 Nordic Countries
9 China
9.1 China Depression-MDD Drugs Market Size (2020-2031)
9.2 China Depression-MDD Drugs Market Size by Type
9.2.1 China Depression-MDD Drugs Market Size by Type (2020-2025)
9.2.2 China Depression-MDD Drugs Market Size by Type (2026-2031)
9.2.3 China Depression-MDD Drugs Market Share by Type (2020-2031)
9.3 China Depression-MDD Drugs Market Size by Application
9.3.1 China Depression-MDD Drugs Market Size by Application (2020-2025)
9.3.2 China Depression-MDD Drugs Market Size by Application (2026-2031)
9.3.3 China Depression-MDD Drugs Market Share by Application (2020-2031)
10 Asia (Excluding China)
10.1 Asia Depression-MDD Drugs Market Size (2020-2031)
10.2 Asia Depression-MDD Drugs Market Size by Type
10.2.1 Asia Depression-MDD Drugs Market Size by Type (2020-2025)
10.2.2 Asia Depression-MDD Drugs Market Size by Type (2026-2031)
10.2.3 Asia Depression-MDD Drugs Market Share by Type (2020-2031)
10.3 Asia Depression-MDD Drugs Market Size by Application
10.3.1 Asia Depression-MDD Drugs Market Size by Application (2020-2025)
10.3.2 Asia Depression-MDD Drugs Market Size by Application (2026-2031)
10.3.3 Asia Depression-MDD Drugs Market Share by Application (2020-2031)
10.4 Asia Depression-MDD Drugs Market Size by Country
10.4.1 Asia Depression-MDD Drugs Market Size by Country (2020 VS 2024 VS 2031)
10.4.2 Asia Depression-MDD Drugs Market Size by Country (2020-2025)
10.4.3 Asia Depression-MDD Drugs Market Size by Country (2026-2031)
10.4.4 Asia Depression-MDD Drugs Market Share by Country (2020-2031)
10.4.5 Japan
10.4.6 South Korea
10.4.7 Taiwan
10.4.8 Southeast Asia
10.4.9 India
10.4.10 Australia
11 South America, Middle East & Africa
11.1 South America, Middle East & Africa Depression-MDD Drugs Market Size (2020-2031)
11.2 South America, Middle East & Africa Depression-MDD Drugs Market Size by Type
11.2.1 South America, Middle East & Africa Depression-MDD Drugs Market Size by Type (2020-2025)
11.2.2 South America, Middle East & Africa Depression-MDD Drugs Market Size by Type (2026-2031)
11.2.3 South America, Middle East & Africa Depression-MDD Drugs Market Share by Type (2020-2031)
11.3 South America, Middle East & Africa Depression-MDD Drugs Market Size by Application
11.3.1 South America, Middle East & Africa Depression-MDD Drugs Market Size by Application (2020-2025)
11.3.2 South America, Middle East & Africa Depression-MDD Drugs Market Size by Application (2026-2031)
11.3.3 South America, Middle East & Africa Depression-MDD Drugs Market Share by Application (2020-2031)
11.4 South America, Middle East & Africa Depression-MDD Drugs Market Size by Country
11.4.1 South America, Middle East & Africa Depression-MDD Drugs Market Size by Country (2020 VS 2024 VS 2031)
11.4.2 South America, Middle East & Africa Depression-MDD Drugs Market Size by Country (2020-2025)
11.4.3 South America, Middle East & Africa Depression-MDD Drugs Market Size by Country (2026-2031)
11.4.4 South America, Middle East & Africa Depression-MDD Drugs Market Share by Country (2020-2031)
11.4.5 Brazil
11.4.6 South Africa
11.4.7 Saudi Arabia
11.4.8 Turkey
11.4.9 Argentina
11.4.9 UAE
11.4.9 Egypt
11.4.9 Chile
12 Concluding Insights
13 Appendix
13.1 Reasons for Doing This Study
13.2 Research Methodology
13.3 Research Process
13.4 Authors List of This Report
13.5 Data Source
13.5.1 Secondary Sources
13.5.2 Primary Sources
13.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.